본문 바로가기

Organoid

Islet Organoid

The Islet Organoid is an innovative bio-therapeutic solution that three-dimensionally reconstructs insulin-secreting cells derived from induced pluripotent stem cells.

Islet Organoid


A New Paradigm in Diabetes Treatment

The Islet Organoid is an innovative bio-therapeutic solution that three-dimensionally reconstructs insulin-secreting cells derived from induced pluripotent stem cells (hiPSCs). While conventional diabetes treatments—such as insulin injections or pumps—have focused primarily on symptom management, islet organoids represent a fundamental therapeutic approach by autonomously sensing blood glucose levels and secreting insulin within the patient’s body..
This technology is primarily targeted toward insulin-dependent Type 1 diabetes patients. Following transplantation, islet organoids function in a manner highly comparable to native human islets, enabling long-term and stable glycemic control. As a result, this approach has the potential not only to dramatically improve patients’ quality of life, but also to reshape and ultimately replace existing diabetes treatment paradigms on a global scale.
Our objective extends beyond technological development. We are committed to clinical safety, scalable manufacturing, and international regulatory approval, with commercialization as a core goal. Islet organoid-based therapeutics are poised to become a new standard of care in diabetes treatment and to serve as a key growth engine at the forefront of biopharmaceutical innovation.

Key Features of the Islet Organoid

Key Features of the Islet Organoid
  • Universal hiPSC Platform:
    Standardized induced pluripotent stem cells enable broad clinical applicability and scalable manufacturing.
  • Proprietary 3D Static Culture Technology:
    A patented differentiation process (KR Patent Application No. 10-2023-0135187) for robust and reproducible islet organoid production.
  • Organoid-Level Tracking and Real-Time QC:
    Digital well-based tracking combined with non-invasive live readouts enables consistent quality and functional prediction.
  • β-Cell Maturation–Optimized Environment:
    Static culture conditions minimize stress while precisely controlling oxygen and nutrient distribution.
  • GMP-Ready Manufacturing Design:
    Process parameters, documentation, and electronic batch release criteria are embedded for seamless GMP translation.

Major Hormone Expression in Islet Organoids

Major Hormone Expression in Islet Organoids
  • Insulin (β-cells)
  • Glucagon (α-cells)
  • Somatostatin (δ-cells)

3D static culture islet organoids faithfully recapitulate the endocrine composition of human pancreatic islets and functionally secrete key hormones, including insulin, glucagon, and somatostatin. Upon glucose stimulation, insulin (or C-peptide) secretion is increased; under low-glucose or arginine conditions, glucagon secretion is induced; and somatostatin is released during homeostatic regulation. Together, these responses demonstrate a physiologically relevant hormonal network closely resembling that of native human islets.

Company

Company Overview

Welcome Message

Vision & Mission
Location

Business

Stem Cell Therapy

Organoid

Stem Cell and CDMO Business

Health&Beauty Business

R&D

Core Technology

Global R&D Center
Stem Cell GMP Center

Investors

Notice

IR

PR